In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.
Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS
Here are the key trials we discussed:
1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/27332902/
2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/27069074/
3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/29224502/
https://pubmed.ncbi.nlm.nih.gov/35830649/
4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):
https://pubmed.ncbi.nlm.nih.gov/35867960/
5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4
6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):
https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_4
7. HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):
https://onlinelibrary.wiley.com/doi/10.1002/hon.3196_LBA5
Listen to all your favourite podcasts with AI-powered features
Listen to the best highlights from the podcasts you love and dive into the full episode
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more